<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19015" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Catatonic Schizophrenia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Ankit</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mitra</surname>
            <given-names>Paroma</given-names>
          </name>
          <aff>New York University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ankit Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Paroma Mitra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19015.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Catatonic schizophrenia is one of the classical clinical subtypes of schizophrenia. The concept of catatonic symptoms in schizophrenia has changed throughout the years, with relevant implications in the treatment approach and prognosis. This activity reviews the evaluation and management of catatonic schizophrenia and highlights the role of the healthcare team in the care of patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pathophysiology of catatonic schizophrenia.</p></list-item><list-item><p>Review the physical exam findings associated with catatonic schizophrenia.</p></list-item><list-item><p>Summarize management considerations for patients with catatonic schizophrenia and compare with treatment for catatonia secondary to mood or neurological disorders.</p></list-item><list-item><p>Outline the importance of improving care coordination amongst the interprofessional team to improve outcomes for patients with catatonic schizophrenia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19015&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19015">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19015.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Schizophrenia was divided into five subtypes, including disorganized schizophrenia, paranoid schizophrenia, residual schizophrenia, undifferentiated schizophrenia, and catatonic schizophrenia per the Diagnostic and Statistical Manual of Mental Disorders (DSM IV). In 2013 the American Psychiatric Association (APA) combined all the subtypes under the general category of schizophrenia. "Catatonia" is a word that has undergone multiple definitions and loosely is associated with multiple psychomotor abnormalities and behavioral dysregulation.<xref ref-type="bibr" rid="article-19015.r1">[1]</xref>&#x000a0;</p>
        <p>Features of catatonia had been described since the 1800s&#x000a0;by prominent physicians such as Kahlbaum and even Kraepelin, who defined catatonia within the larger definition of dementia praecox.<xref ref-type="bibr" rid="article-19015.r2">[2]</xref>&#x000a0;There exist many suggested theories elucidating the etiology of catatonia.&#x000a0;Kahlbaum has ultimately been credited with the understanding that symptoms such as stupor and catalepsy were part of a larger syndrome of psychomotor abnormalities, which he termed as "catatonia." This can be a part of a larger schizophrenic illness or even a bipolar affective illness or medical illness.<xref ref-type="bibr" rid="article-19015.r3">[3]</xref><xref ref-type="bibr" rid="article-19015.r4">[4]</xref></p>
        <p>The advent of DSM-V has placed catatonia in its own category with schizophrenia as a specifier. Further, there are three types of catatonia that have been classified, including akinetic, hyperkinetic, and malignant catatonia.<xref ref-type="bibr" rid="article-19015.r5">[5]</xref></p>
      </sec>
      <sec id="article-19015.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of catatonia is multifactorial. One theory is that GABAergic (gamma-aminobutyric acid) neurotransmitters, which regulate both emotional and cognitive functions, become disrupted, leading to catatonic symptoms.<xref ref-type="bibr" rid="article-19015.r6">[6]</xref>&#x000a0;This theory postulates that severe negative emotions can cause "tonic immobility," leading to a lack of inhibition at the orbitofrontal cortex (OFC) and hence dysregulation between the ventromedial prefrontal cortex (VMPFC) and the dorsolateral prefrontal cortex (DLPFC), which can cause catatonic symptoms. The DLPFC helps with the cognitive understanding of negative emotions.</p>
      </sec>
      <sec id="article-19015.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The epidemiology of catatonic schizophrenia can be multivariate. It is said that about 10% of patients in psychiatric inpatient services have catatonic features.<xref ref-type="bibr" rid="article-19015.r7">[7]</xref> On the one hand, the older school of psychiatry associated schizophrenia with catatonia, while newer epidemiological studies show that 20% of patients with catatonia have schizophrenia, and about 45% have symptoms of mood disorders and medical illness.<xref ref-type="bibr" rid="article-19015.r8">[8]</xref>&#x000a0;</p>
        <p>One prospective study showed that 7.6% of persons diagnosed with schizophrenia have catatonia.<xref ref-type="bibr" rid="article-19015.r9">[9]</xref>&#x000a0;Other studies show that 10%-25% of patients with schizophrenia in the inpatient services can be classified into catatonic schizophrenia, especially when screening tools are used. This can be present at any point-first presentation schizophrenia in someone with lifelong schizophrenia with multiple prior episodes.<xref ref-type="bibr" rid="article-19015.r10">[10]</xref></p>
      </sec>
      <sec id="article-19015.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Dopamine has been cited as a cause of immobility and stupor, and the initial studies researched the role of dopamine in catatonia. However, these studies have been found to be inconclusive.<xref ref-type="bibr" rid="article-19015.r11">[11]</xref></p>
        <p>The N-methyl D-aspartate (NMDA) receptor has been studied extensively both clinically and in mice studies. NMDA encephalitis can produce catatonia-like symptoms.<xref ref-type="bibr" rid="article-19015.r12">[12]</xref> Given that, there have been reports of the use of anti-NMDA agents like amantadine in the treatment of catatonia.<xref ref-type="bibr" rid="article-19015.r13">[13]</xref>&#x000a0;The neurotransmitter that is most associated with catatonia is GABA (gamma-amino-butyric acid), and it has been studied extensively. There is decreased GABAergic activity that has been detected in the left sensorimotor cortex via positron emission tomography (PET) imaging.<xref ref-type="bibr" rid="article-19015.r14">[14]</xref> More importantly, GABAergic drugs are the most effective in treating catatonia.<xref ref-type="bibr" rid="article-19015.r13">[13]</xref></p>
      </sec>
      <sec id="article-19015.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Catatonia again is a complex combination of psychomotor abnormalities and mood and thought processes. There are at least forty different signs and symptoms that have been associated with catatonia. The Diagnostic and Statistical Manual V has criteria for catatonia with specifiers, including that for schizophrenia. Three of the twelve symptoms must be present.<xref ref-type="bibr" rid="article-19015.r15">[15]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Catalepsy (i.e., passive induction of posture held against gravity)</p>
          </list-item>
          <list-item>
            <p>Waxy flexibility (i.e., slight and even resistance to positioning)</p>
          </list-item>
          <list-item>
            <p>Stupor (no psychomotor activity; not actively relating to the environment)</p>
          </list-item>
          <list-item>
            <p>Agitation, not influenced by external stimuli</p>
          </list-item>
          <list-item>
            <p>Mutism (i.e., no or little, verbal response but this is not applicable if there is established aphasia)</p>
          </list-item>
          <list-item>
            <p>Negativism (i.e., opposing or not responding to external stimuli)</p>
          </list-item>
          <list-item>
            <p>Posturing (i.e., spontaneous and active maintenance of a posture against gravity)</p>
          </list-item>
          <list-item>
            <p>Mannerisms (i.e., odd caricature of normal actions)</p>
          </list-item>
          <list-item>
            <p>Stereotypies (i.e., repetitive, abnormally frequent, non-goal-directed movements)</p>
          </list-item>
          <list-item>
            <p>Grimacing</p>
          </list-item>
          <list-item>
            <p>Echolalia (i.e., mimicking another's speech)</p>
          </list-item>
          <list-item>
            <p>Echopraxia (i.e., mimicking another's movements)</p>
          </list-item>
        </list>
        <p>Walter's paper categorizes the symptoms into four major categories: 1. Motor signs (such as immobility) 2. Behavioral signs (negativism) 3. Autonomic instability (tachycardia, hyperthermia) 4. Inability to suppress motor functions (stereotypy, echolalia, echopraxia).<xref ref-type="bibr" rid="article-19015.r16">[16]</xref></p>
        <p>A complete psychiatric history, along with collateral information and a complete neurological examination is key to diagnosing catatonia in a person with schizophrenia. The onset and duration of symptom onset are key to understanding catatonia.</p>
      </sec>
      <sec id="article-19015.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>There is now more importance placed now on neuroimaging in cases of catatonia as there has been a noted decrease in functioning in the motor regions of the parietal and frontal cortexes of the cerebrum. Blood chemistries, blood count, serum iron, and even lumbar puncture for autoimmune antibodies for more severe cases of catatonia may be indicated.</p>
        <p>The best way to evaluate for symptoms of catatonia is via the Bush Francis Catatonia Rating Scale (BCFRS).<xref ref-type="bibr" rid="article-19015.r17">[17]</xref>&#x000a0;This is a 23 item scale, the first 14 are screening items, and two of these 14 need to be present for a positive diagnosis. The severity and description and schema are detailed.<xref ref-type="bibr" rid="article-19015.r18">[18]</xref> The first 14 items described as screeners include excitement, immobility/stupor, staring, posturing, grimacing, stereotypy, echopraxia/echolalia, withdrawal, mannerisms, verbigeration, rigidity, negativism, and waxy flexibility. Additional items that can be evaluated are impulsivity, automatic obedience, mitgehen, gegenhalten, ambitendency, grasp reflex, perseveration, combativeness, and autonomic abnormality.</p>
        <p>A benzodiazepine challenge is warranted to reveal a positive diagnosis. Often 2 mg of lorazepam is given PO or IV to a patient, and remission of symptoms can be seen in 10 minutes. Studies have shown at least a 60% change in symptom presentation.<xref ref-type="bibr" rid="article-19015.r13">[13]</xref></p>
      </sec>
      <sec id="article-19015.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The initial management includes supportive measures such as IV fluids and even nasogastric tubes given that patients with catatonia are susceptible to malnutrition, dehydration, pneumonia, etc. The key is early identification of catatonia in a patient with schizophrenia and initiation of treatment.<xref ref-type="bibr" rid="article-19015.r13">[13]</xref></p>
        <p>If a patient is on anti-psychotic medication, this should be stopped immediately, as this may contribute to catatonia in schizophrenia.</p>
        <p>The treatment of catatonia in schizophrenia is with benzodiazepines as the first line of treatment and then electroconvulsive therapy (ECT). The Bush-Francis group has conducted a study where they have shown a reduction in the BCFRS by 60% by administrating 2 mg of lorazepam in 10 minutes.<xref ref-type="bibr" rid="article-19015.r17">[17]</xref><xref ref-type="bibr" rid="article-19015.r18">[18]</xref> Multiple case reports, studies, and clinical evidence now points towards the use of benzodiazepines as the standard of treatment of catatonia.<xref ref-type="bibr" rid="article-19015.r13">[13]</xref><xref ref-type="bibr" rid="article-19015.r19">[19]</xref></p>
        <p>In a study of 107 people, it has been seen that two-thirds of patients studied responded adequately to the use of lorazepam. Only one-third were in remission.<xref ref-type="bibr" rid="article-19015.r20">[20]</xref>&#x000a0;A large proportion of these were patients with a chronic psychotic disorder (49%), and&#x000a0;they were trialed between 3&#x000a0;to 6 mg/day IV of lorazepam. The theory that benzodiazepines are partially effective in catatonic schizophrenia has been replicated on multiple clinical trials by other groups with a larger sample size as well.<xref ref-type="bibr" rid="article-19015.r19">[19]</xref><xref ref-type="bibr" rid="article-19015.r21">[21]</xref> Most studies advocate for doses of lorazepam between 8&#x000a0;to 24 mg/day without causing oversedation. <xref ref-type="bibr" rid="article-19015.r22">[22]</xref>&#x000a0;Patients with catatonia can take between 3&#x000a0;to 7 days to respond.</p>
        <p>ECT is to be used for patients that have failed an adequate trial of benzodiazepines. ECT is also used for rapid and malignant catatonia with autonomic dysfunction. Specifically, in catatonic schizophrenia, ECT is the treatment of choice. There have been large-scale trials conducted for patients&#x000a0;with schizophrenia with intractable catatonia.<xref ref-type="bibr" rid="article-19015.r23">[23]</xref>&#x000a0;Results have shown ECT to be effective in about 100% of persons with schizophrenia; however, there is relapse within one year. The largest reviews for catatonic schizophrenia and treatment via ECT have been the chart review study conducted in Iowa.<xref ref-type="bibr" rid="article-19015.r24">[24]</xref>&#x000a0;Results of the study show about 53% of persons with catatonic schizophrenia respond to ECT.</p>
        <p>Other agents such as zolpidem have been studied for schizophrenia but not for catatonic schizophrenia. However, anti-NMDA agents like amantadine and memantine have been studied in single cases of catatonic schizophrenia and have shown some efficacy.<xref ref-type="bibr" rid="article-19015.r25">[25]</xref></p>
        <p>Lithium has also been studied but has not been studied exclusively for catatonic schizophrenia. Rather its efficacy is seen in cases of recurrent catatonia mostly associated with mood disorders.<xref ref-type="bibr" rid="article-19015.r26">[26]</xref></p>
      </sec>
      <sec id="article-19015.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Neuroleptic malignant syndrome</p>
          </list-item>
          <list-item>
            <p>Serotonin syndrome</p>
          </list-item>
          <list-item>
            <p>Malignant hyperthermia</p>
          </list-item>
          <list-item>
            <p>Akinetic mutism</p>
          </list-item>
          <list-item>
            <p>Epilepsy (nonconvulsive status epilepticus)</p>
          </list-item>
          <list-item>
            <p>Locked-in syndrome</p>
          </list-item>
          <list-item>
            <p>Stiff-person syndrome</p>
          </list-item>
          <list-item>
            <p>Parkinson disease</p>
          </list-item>
          <list-item>
            <p>Stroke</p>
          </list-item>
          <list-item>
            <p>Delirium</p>
          </list-item>
          <list-item>
            <p>Dementia</p>
          </list-item>
          <list-item>
            <p>Elective mutism</p>
          </list-item>
          <list-item>
            <p>Encephalitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19015.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of catatonia is favorable if detected early and treated. It is more favorable if catatonia is associated with mood or anxiety disorders. Catatonic schizophrenia carries a poorer prognosis. Most clinical studies that have focused on the use of lorazepam in the treatment of catatonic schizophrenia show poor results.<xref ref-type="bibr" rid="article-19015.r19">[19]</xref></p>
        <p>Another acclaimed study also studied the effects of lorazepam on patients with catatonic schizophrenia and catatonia secondary to other disorders, and importantly patients with catatonic schizophrenia showed only partial remission while the others showed full remission.<xref ref-type="bibr" rid="article-19015.r27">[27]</xref></p>
        <p>The use of ECT is encouraged in catatonia that does not respond to benzodiazepines. However, studies continue to show that catatonic schizophrenia also responds more poorly to ECT compared to catatonia secondary to mood disorders.<xref ref-type="bibr" rid="article-19015.r28">[28]</xref>&#x000a0;Several theories propose that catatonic schizophrenia is "phenomenologically different" and hence does not respond as well to the use of benzodiazepines or ECT.<xref ref-type="bibr" rid="article-19015.r29">[29]</xref></p>
        <p>The group lead by Gabor S.Ungvari discusses the psychomotor symptoms that are seen in chronic schizophrenia and underdiagnosis and recognition of the same. Chronic patients may display more stereotypes, automatic mannerisms, and bizarre postures.<xref ref-type="bibr" rid="article-19015.r29">[29]</xref> This carries a worse prognosis in chronic&#x000a0;schizophrenia.<xref ref-type="bibr" rid="article-19015.r30">[30]</xref> Gabor S.Ungvari's group has studied catatonic schizophrenia in the four main domains of motor symptoms, including negative/withdrawn phenomena, automatic phenomena, repetitive phenomena, and agitated phenomena. There are associations between sex, younger age, parkinsonism, and negative symptoms of schizophrenia with catatonia.<xref ref-type="bibr" rid="article-19015.r10">[10]</xref><xref ref-type="bibr" rid="article-19015.r30">[30]</xref>&#x000a0;</p>
        <p>This group focuses on the presence of psychomotor symptoms in both acute and chronic schizophrenia and the recognition of catatonia within this phenomenon.</p>
      </sec>
      <sec id="article-19015.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Given that acute catatonia can have its origin with medical or neurological illnesses, initial monitoring with vitals signs notation and&#x000a0;treatment with intravenous fluids and nasogastric tubes are warranted. Complications can include aspiration pneumonia, dehydration, embolisms, pressure ulcers, and malnutrition. This can be life-threatening.<xref ref-type="bibr" rid="article-19015.r31">[31]</xref></p>
      </sec>
      <sec id="article-19015.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The most important aspect includes early detection and treatment. When schizophrenia is traditionally discussed, the focus is usually on the positive symptoms of schizophrenia and less on the negative symptoms. Catatonic schizophrenia is a small percentage of the larger spectrum of a chronic psychotic disorder. However, given its poor prognosis, patients and families would benefit from understanding the nature of symptoms such as stereotypy, automated mannerisms, and immobility to better identify its manifestations.</p>
      </sec>
      <sec id="article-19015.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Catatonia was traditionally associated with schizophrenia. In the latest version of the DSM V (Diagnostic and Statistical Manual V), it has its own category.</p>
          </list-item>
          <list-item>
            <p>When prominent negative symptoms and psychomotor symptoms are noted in a patient with schizophrenia, consider catatonic schizophrenia.</p>
          </list-item>
          <list-item>
            <p>Catatonic schizophrenia can be a medical emergency; the BFCRS must be used for early detection. Medical support is often warranted and necessary. Underlying medical and neurological causes must be ruled out.</p>
          </list-item>
          <list-item>
            <p>Treat medical complications first.</p>
          </list-item>
          <list-item>
            <p>A benzodiazepine challenge is warranted. Treat aggressively with IV benzodiazepines for at least 3-7 days. Clinical trials have shown the use of up to 24 mg IV lorazepam.</p>
          </list-item>
          <list-item>
            <p>Catatonic schizophrenia has a poor response to benzodiazepines and often responds better to ECT.</p>
          </list-item>
          <list-item>
            <p>These patients have a poor prognosis, and relapse and remission of symptoms are usually seen. Maintenance ECT is considered helpful.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19015.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>One way of enhancing health care outcomes is by collaborating with both medical and neurological staff as catatonic schizophrenia can present as an emergency with life-threatening medical complications and autonomic instability. It is important to understand that underlying delirium or medical or neurological conditions can precipitate a catatonic state.</p>
        <p>An interprofessional team consisting of a psychiatrist, hospitalist, nursing services, nutritional, and peer counselor would be effective in providing round-the-clock care to the patient with catatonic schizophrenia. Often extensive psychoeducation with an emphasis on prognosis is helpful for the family of the patient. The hospital stays are longer than regular, and patients often require months-long treatment in an inpatient service. In the outpatient setting, the benzodiazepine must be tapered off slowly to prevent relapse. It is important for both inpatient and outpatient teams to collaborate on care to prevent relapse of symptoms.</p>
      </sec>
      <sec id="article-19015.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19015&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19015">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/mental-health/catatonic-schizophrenia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19015">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19015/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19015">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19015.s16">
        <title>References</title>
        <ref id="article-19015.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungvari</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Gerevich</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tak&#x000e1;cs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gazdag</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Schizophrenia with prominent catatonic features: A selective review.</article-title>
            <source>Schizophr Res</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>200</volume>
            <fpage>77</fpage>
            <page-range>77-84</page-range>
            <pub-id pub-id-type="pmid">28818505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shorter</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Catatonia is not schizophrenia: Kraepelin's error and the need to recognize catatonia as an independent syndrome in medical nomenclature.</article-title>
            <source>Schizophr Bull</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>314</fpage>
            <page-range>314-20</page-range>
            <pub-id pub-id-type="pmid">19586994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caroff</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Hurford</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bleier</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Gorton</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Recurrent Idiopathic Catatonia: Implications beyond the Diagnostic and Statistical Manual of Mental Disorders 5th Edition.</article-title>
            <source>Clin Psychopharmacol Neurosci</source>
            <year>2015</year>
            <month>Aug</month>
            <day>31</day>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>218</fpage>
            <page-range>218-21</page-range>
            <pub-id pub-id-type="pmid">26243853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peralta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cuesta</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Mata</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>The Kahlbaum syndrome: a study of its clinical validity, nosological status, and relationship with schizophrenia and mood disorder.</article-title>
            <source>Compr Psychiatry</source>
            <year>1997</year>
            <season>Jan-Feb</season>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-7</page-range>
            <pub-id pub-id-type="pmid">8980874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Catatonia: diagnosis, classification, and treatment.</article-title>
            <source>Curr Psychiatry Rep</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>180</fpage>
            <page-range>180-5</page-range>
            <pub-id pub-id-type="pmid">20425278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Choucha</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Neurobiological Approach of Catatonia and Treatment Perspectives.</article-title>
            <source>Front Psychiatry</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>182</fpage>
            <pub-id pub-id-type="pmid">26733892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Appiani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bertelsen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bolwig</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Br&#x000e4;unig</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Caroff</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Cavanna</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cottencin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cuesta</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dhossche</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fricchione</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Gazdag</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ghaziuddin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Healy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kr&#x000fc;ger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Mazurek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McCall</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>McDaniel</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Northoff</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peralta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Petrides</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rosebush</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rummans</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Shorter</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vaiva</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wachtel</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.</article-title>
            <source>J ECT</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>246</fpage>
            <page-range>246-7</page-range>
            <pub-id pub-id-type="pmid">21099376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosebush</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Mazurek</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Catatonia and its treatment.</article-title>
            <source>Schizophr Bull</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>239</fpage>
            <page-range>239-42</page-range>
            <pub-id pub-id-type="pmid">19969591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleinhaus</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harlap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perrin</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Manor</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Weiser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harkavy-Friedman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lichtenberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Malaspina</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Catatonic schizophrenia: a cohort prospective study.</article-title>
            <source>Schizophr Bull</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>331</fpage>
            <page-range>331-7</page-range>
            <pub-id pub-id-type="pmid">20693343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungvari</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Goggins</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gerevich</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Schizophrenia with prominent catatonic features ('catatonic schizophrenia'). II. Factor analysis of the catatonic syndrome.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>2007</year>
            <month>Mar</month>
            <day>30</day>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>462</fpage>
            <page-range>462-8</page-range>
            <pub-id pub-id-type="pmid">17188791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schirrmeister</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gerhard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ellitok</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beckmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reske</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>St&#x000f6;ber</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Disturbed neural circuits in a subtype of chronic catatonic schizophrenia demonstrated by F-18-FDG-PET and F-18-DOPA-PET.</article-title>
            <source>J Neural Transm (Vienna)</source>
            <year>2001</year>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>661</fpage>
            <page-range>661-70</page-range>
            <pub-id pub-id-type="pmid">11478418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Martinez-Hernandez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Balice-Gordon</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.</article-title>
            <source>Lancet Neurol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-74</page-range>
            <pub-id pub-id-type="pmid">21163445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sienaert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dhossche</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Vancampfort</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Hert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gazdag</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A clinical review of the treatment of catatonia.</article-title>
            <source>Front Psychiatry</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>181</fpage>
            <pub-id pub-id-type="pmid">25538636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Northoff</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Steinke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Czcervenka</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ulrich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Danos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kropf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bogerts</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding.</article-title>
            <source>J Neurol Neurosurg Psychiatry</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>445</fpage>
            <page-range>445-50</page-range>
            <pub-id pub-id-type="pmid">10486389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walther</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Strik</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Catatonia.</article-title>
            <source>CNS Spectr</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>341</fpage>
            <page-range>341-8</page-range>
            <pub-id pub-id-type="pmid">27255726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walther</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Strik</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Motor symptoms and schizophrenia.</article-title>
            <source>Neuropsychobiology</source>
            <year>2012</year>
            <volume>66</volume>
            <issue>2</issue>
            <fpage>77</fpage>
            <page-range>77-92</page-range>
            <pub-id pub-id-type="pmid">22814247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bush</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petrides</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dowling</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Catatonia. I. Rating scale and standardized examination.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-36</page-range>
            <pub-id pub-id-type="pmid">8686483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bush</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petrides</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dowling</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Catatonia. II. Treatment with lorazepam and electroconvulsive therapy.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-43</page-range>
            <pub-id pub-id-type="pmid">8686484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungvari</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>142</volume>
            <issue>4</issue>
            <fpage>393</fpage>
            <page-range>393-8</page-range>
            <pub-id pub-id-type="pmid">10229064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narayanaswamy</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tibrewal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zutshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srinivasaraju</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Math</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Clinical predictors of response to treatment in catatonia.</article-title>
            <source>Gen Hosp Psychiatry</source>
            <year>2012</year>
            <season>May-Jun</season>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>312</fpage>
            <page-range>312-6</page-range>
            <pub-id pub-id-type="pmid">22387048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beckmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fritze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Franzek</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavourable long-term course. A 5-year follow-up study of 50 chronic schizophrenics.</article-title>
            <source>Neuropsychobiology</source>
            <year>1992</year>
            <volume>26</volume>
            <issue>1-2</issue>
            <fpage>50</fpage>
            <page-range>50-8</page-range>
            <pub-id pub-id-type="pmid">1361971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>2006</year>
            <month>Aug</month>
            <day>30</day>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>1182</fpage>
            <page-range>1182-3; author reply 1184-5</page-range>
            <pub-id pub-id-type="pmid">16675086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Awata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>One-year outcome after response to ECT in middle-aged and elderly patients with intractable catatonic schizophrenia.</article-title>
            <source>J ECT</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-106</page-range>
            <pub-id pub-id-type="pmid">15167426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrison</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Catatonia: prediction of outcome.</article-title>
            <source>Compr Psychiatry</source>
            <year>1974</year>
            <season>Jul-Aug</season>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-24</page-range>
            <pub-id pub-id-type="pmid">4412345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muneoka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shirayama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawabe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Improvement of mutism in a catatonic schizophrenia case by add-on treatment with amantadine.</article-title>
            <source>Pharmacopsychiatry</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>151</fpage>
            <page-range>151-2</page-range>
            <pub-id pub-id-type="pmid">20571993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petursson</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Lithium treatment of a patient with periodic catatonia.</article-title>
            <source>Acta Psychiatr Scand</source>
            <year>1976</year>
            <month>Oct</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>248</fpage>
            <page-range>248-53</page-range>
            <pub-id pub-id-type="pmid">998323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Hallmayer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Catatonia in a psychiatric intensive care facility: incidence and response to benzodiazepines.</article-title>
            <source>Ann Clin Psychiatry</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-96</page-range>
            <pub-id pub-id-type="pmid">10907800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rohland</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Jacoby</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>ECT in the treatment of the catatonic syndrome.</article-title>
            <source>J Affect Disord</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>255</fpage>
            <page-range>255-61</page-range>
            <pub-id pub-id-type="pmid">8126312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungvari</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Caroff</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Gerevich</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders.</article-title>
            <source>Schizophr Bull</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>231</fpage>
            <page-range>231-8</page-range>
            <pub-id pub-id-type="pmid">19776208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ungvari</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Schizophrenia with prominent catatonic features ('catatonic schizophrenia'): I. Demographic and clinical correlates in the chronic phase.</article-title>
            <source>Prog Neuropsychopharmacol Biol Psychiatry</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-38</page-range>
            <pub-id pub-id-type="pmid">15610942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19015.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clinebell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Azzam</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Gopalan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Haskett</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for preventing common medical complications of catatonia: case report and literature review.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>644</fpage>
            <page-range>644-51</page-range>
            <pub-id pub-id-type="pmid">25004188</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
